MX2022008850A - Cannabinoides para uso en tratamiento. - Google Patents

Cannabinoides para uso en tratamiento.

Info

Publication number
MX2022008850A
MX2022008850A MX2022008850A MX2022008850A MX2022008850A MX 2022008850 A MX2022008850 A MX 2022008850A MX 2022008850 A MX2022008850 A MX 2022008850A MX 2022008850 A MX2022008850 A MX 2022008850A MX 2022008850 A MX2022008850 A MX 2022008850A
Authority
MX
Mexico
Prior art keywords
sub
cannabinoids
treatment
phytocannabinoids
a3ar
Prior art date
Application number
MX2022008850A
Other languages
English (en)
Inventor
Pnina Fishman
Inbal Itzhak
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2022008850A publication Critical patent/MX2022008850A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los cannabinoides se usan para tratar enfermedades o trastornos tratables por un activador del receptor de adenosina A3(A3AR). El efecto cannabinoide se ejerce a través del A3AR. Los cannabinoides pueden seleccionarse de fitocannabinoides naturales, derivados sintéticos de fitocannabinoides, extractos de planta de cannabis y otros.
MX2022008850A 2020-01-16 2021-01-14 Cannabinoides para uso en tratamiento. MX2022008850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL272078A IL272078A (en) 2020-01-16 2020-01-16 Cannabinoids for use in therapy
PCT/IL2021/050046 WO2021144799A1 (en) 2020-01-16 2021-01-14 Cannabinoids for use in treatment

Publications (1)

Publication Number Publication Date
MX2022008850A true MX2022008850A (es) 2022-08-10

Family

ID=76863896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008850A MX2022008850A (es) 2020-01-16 2021-01-14 Cannabinoides para uso en tratamiento.

Country Status (11)

Country Link
US (1) US20230049415A1 (es)
EP (1) EP4090324A1 (es)
JP (1) JP2023510003A (es)
KR (1) KR20220137661A (es)
CN (1) CN114980873A (es)
AU (1) AU2021207766A1 (es)
BR (1) BR112022013991A2 (es)
CA (1) CA3164880A1 (es)
IL (1) IL272078A (es)
MX (1) MX2022008850A (es)
WO (1) WO2021144799A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229494A1 (en) * 2021-08-19 2023-02-23 Yun Kau Tam A pharmaceutical platform technology for drug discovery and consumer health product development

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
ATE371191T1 (de) * 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
WO2004045627A1 (en) 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
ATE540673T1 (de) 2005-11-30 2012-01-15 Can Fite Biopharma Ltd Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis
MX2007010896A (es) * 2007-09-06 2009-03-06 Univ Mexico Nacional Autonoma Uso de sales de adenosina para la preparacion de productos farmaceuticos para el tratamiento del cancer.
US8846635B2 (en) 2007-10-15 2014-09-30 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US20130169785A1 (en) * 2011-12-30 2013-07-04 Agco Corporation Method of detecting and improving operator situational awareness on agricultural machines
EP2806878A1 (en) 2012-01-23 2014-12-03 Can-Fite Biopharma Ltd. Treatment of liver conditions
GB2515312A (en) * 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments

Also Published As

Publication number Publication date
BR112022013991A2 (pt) 2022-10-11
US20230049415A1 (en) 2023-02-16
KR20220137661A (ko) 2022-10-12
AU2021207766A1 (en) 2022-07-21
WO2021144799A1 (en) 2021-07-22
IL272078A (en) 2021-07-29
CA3164880A1 (en) 2021-07-22
JP2023510003A (ja) 2023-03-10
CN114980873A (zh) 2022-08-30
EP4090324A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
BR112021024686A2 (pt) Produto de bolsa de nicotina
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
MX2021000020A (es) Composicion y metodo para tratar el dolor.
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO992400L (no) Nye substituerte pyrazolderivater
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
MA25406A1 (fr) Derives de 4,5- diaryl -3 (2h)-furanone utilises en tant que inhibiteurs de la cyclooxygenase-2
MX2022008850A (es) Cannabinoides para uso en tratamiento.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
RU2009149684A (ru) Комбинации вазоактивных веществ с эстрогенами и их применение для лечения сексуальных дисфункций у женщин
Kopalli et al. NLRP3 inflammasome activation inhibitors in inflammation-associated cancer immunotherapy: an update on the recent patents
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
Rajabzadeh et al. Honey and Vitamin E Restore the Plasma Level of Gonadal Hormones and Improve the Fertilization Capacity in Noise-Stressed Rats.
MXPA03000089A (es) Uso de inhibidores de cinasa de tirosina de proteina de egf-r para prevenir el fotoenvejecimiento de la piel humana.
MX2023007027A (es) Derivado de cannabinoide como compuesto farmaceuticamente activo y metodo de preparacion del mismo.
MX2021007160A (es) Una semilla de planta artificial y usos de esta.
Salehi et al. Evaluation of the effective methods of seed dormancy breaking in medicinal plant of Bilhar (Dorema aucheri)